Welcome to our dedicated page for Lilly Eli & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Eli Lilly and Company (NYSE: LLY) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents help investors understand Lilly’s capital structure, governance, financing activities and material events affecting the business.
Lilly’s common stock and several series of notes are registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on the New York Stock Exchange, including common stock under the symbol LLY and multiple note series with maturities ranging from 2026 to 2061. Recent Form 8-K filings disclose items such as quarterly financial results furnished under Item 2.02, other events under Item 8.01, and governance changes under Item 5.02. For example, an August 2025 Form 8-K describes an underwriting agreement for floating-rate notes due 2028 and fixed-rate notes due between 2028 and 2065, while a November 2025 Form 8-K reports the election of a new independent director to Lilly’s board.
Through this page, users can review current and historical 8-Ks, along with other core filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q when available. These filings typically include details on Lilly’s therapeutic focus areas—such as cardiometabolic health, obesity, oncology, immunology and neuroscience—its risk factors, research and development programs, and financial condition.
Stock Titan enhances access to Lilly’s filings by pairing real-time EDGAR updates with AI-powered summaries. AI-generated overviews can help explain the significance of complex documents, such as new debt offerings, governance changes or major transactions, in plain language. Users can also quickly identify insider and executive-related disclosures when they appear in Forms 3, 4 or 5, and track how financing decisions, such as multi-series note issuances, fit into Lilly’s broader capital strategy.
Whether you are analyzing LLY’s latest 10-K, reviewing 10-Q trends, or examining 8-Ks related to acquisitions, collaborations and manufacturing investments, this filings hub offers a structured view of the company’s regulatory record with tools to make dense disclosures easier to interpret.
On 08/12/2025, Director J. Erik Fyrwald reported purchases of Eli Lilly & Co. (LLY) common stock totaling 1,565 shares across two transactions: 686 shares at a weighted average price of $641.996 and 879 shares at $642.586. The Form 4 shows beneficial ownership rising to 73,698.779 shares after the first purchase and to 74,577.779 shares after the second. The filing notes the reported prices are weighted averages across multiple executions within disclosed price ranges and offers to provide detailed per-price execution data on request.
Ilya Yuffa, listed as EVP & President, LLY USA & Global Capab and an officer of Eli Lilly & Co., reported a sale of 1,250 shares of Eli Lilly common stock on 08/11/2025 at a reported price of $627.01 per share.
The Form 4 shows the sale was effected pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Following the reported transaction the form lists 26,259.971 shares beneficially owned by the reporting person in a direct ownership form. No derivative transactions are reported in Table II.
Jamere Jackson, identified as a Director of Eli Lilly & Co. (LLY), reported an acquisition of 200 shares of the company’s common stock on 08/08/2025 at a reported price of $639.563 per share. The Form 4 shows his ownership following the transaction as 9,401.724 shares, held directly.
Eli Lilly (LLY) posted another record quarter. Q2-25 revenue rose 38 % YoY to $15.56 bn, driven by cardiometabolic products (Mounjaro +68 % to $5.20 bn; first-year Zepbound $3.38 bn). Oncology added $2.41 bn (+12 %).
Profitability surged. Net income nearly doubled to $5.66 bn; diluted EPS jumped 92 % to $6.29. Six-month EPS is $9.35 (+62 %). Operating margin expanded as revenue growth outpaced increases in R&D (↑23 %) and SG&A (↑30 %). No special charges occurred this quarter versus $435 m last year.
Balance-sheet trends. Total assets grew to $100.9 bn (-year-end 24: $78.7 bn) mainly from higher receivables and a $3.4 bn inventory build to support GLP-1 demand. Debt increased to $39.9 bn (-year-end: $33.6 bn) after $6.46 bn of new issuances. Cash & equivalents held steady at $3.38 bn; operating cash flow more than doubled to $4.75 bn YTD.
Capital returns & pipeline. Dividend lifted to $3.00/sh (prior-year $2.60). $13.11 bn remains on the $15 bn buyback plan. Business development continues: closed $925 m Wisconsin injectables plant (May) and, post-quarter, announced up to $2.3 bn acquisitions of Verve (cardiovascular gene therapy) and SiteOne (pain).
Outlook signals. U.S. revenue accounted for 69 % of sales; Europe grew 83 % YoY. Management highlights demand but warns of pricing, manufacturing and regulatory risks. No updated guidance included in the excerpt.
Eli Lilly and Company filed a Form 8-K dated 7 Aug 2025 under Item 2.02 to furnish, not file, a press release (Ex. 99.1) that announces the company’s financial results for the quarter ended 30 Jun 2025. The actual earnings figures are not included in this submission; investors must review the accompanying press release for details. No other material transactions or disclosures are presented. The filing re-affirms the company’s NYSE listings for its common stock and various note issues and indicates that Lilly is not an emerging-growth company. The document is purely administrative and carries no immediate financial metrics or guidance.
Eli Lilly & Co. (LLY) filed a Form 144 notice for the proposed sale of restricted shares.
- Seller intends to dispose of 280,000 common shares through Fidelity Capital Markets.
- At the filing’s reference price, the block is worth $223.7 million.
- Eli Lilly has 947.7 million shares outstanding, so the sale represents roughly 0.03 % of the float—small in relation to daily liquidity and unlikely to be dilutive.
- Planned trade date: 24 Jul 2025; exchanges listed: NYSE / NASDAQ.
- The shares trace back to a 10 Feb 1948 gift from the J.K. Lilly Sr. Trust; no other sales were reported in the past three months.
The filer certifies awareness of no undisclosed material adverse information.